Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04884035 · ClinicalTrials.gov registry record · Phase 1

Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma

A Phase 1 study of Lymphoma, B-Cell, sponsored by Celgene.

Recruiting
Registry status
Phase 1
Development phase
174
Enrollment target
20
Study locations

NCT04884035 is a Phase 1 study of Lymphoma, B-Cell that is actively recruiting participants, run by Celgene. The registered enrollment target is 174 participants, below the 196-participant average among 31 other Lymphoma, B-Cell trials with a reported enrollment target (11% lower). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04884035, a Phase 1 study of Lymphoma, B-Cell, is actively recruiting participants, sponsored by Celgene.

RECRUITING
Registry status
Phase 1
Development phase
174 participants
Enrollment target
20
Study locations

Study Summary

This is a Phase 1b study consisting of 2 parts: a dose escalation (Part 1) of CC-220 or CC-99282 added to the standard R-CHOP-21 regimen for first-line treatment of a-BCL. The dose escalation (Part 1) will consist of 2 parallel arms in combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP-21); CC-220 and R-CHOP-21 or CC-99282 and R-CHOP-21. Part 1 will be followed by a randomized dose expansion (Part 2) with CC-220 and/or CC-99282 at the Recommended Phase 2 Dose (RP2D) in combination with R-CHOP-21. A polatuzumab-R-CHP regimen in combination with CC-220 or CC-99282 will be explored with the addition of a new cohort only after the RP2D for the CC-220 and/or CC-99282 and R-CHOP-21 combination has been defined.

Conditions Studied

Lymphoma, B-Cell

Interventions

  • DRUG Cyclophosphamide
  • DRUG Doxorubicin
  • DRUG Rituximab
  • DRUG Vincristine
  • DRUG CC-220

Study Locations (20)

Other

  • Local Institution - 503 - Perth
  • Local Institution - 502 - Waratah
  • Evangelismos General Hospital of Athens - Athens
  • General Hospital of Athens "Laiko" - Athens
  • Attikon University General Hospital - Athens

Florida

  • Mayo Clinic - Jacksonville - Jacksonville
  • Mayo Clinic Jacksonville - PPDS - Jacksonville

Kansas

  • University Of Kansas Medical Center - Kansas City
  • Cancer Center Of Kansas-Wichita - Wichita

Minnesota

  • Mayo Clinic - Rochester - Rochester
  • HealthPartners Cancer Research Center - Saint Louis Park

Utah

  • Local Institution - 168 - Murray
  • Local Institution - 171 - St. George

Arizona

  • Mayo Clinic - Arizona - Scottsdale

California

  • Local Institution - 169 - Duarte

Nebraska

  • University of Nebraska - Fred and Pamela Buffet Center - Omaha

Trial Details

FieldValue
Enrollment Target 174 participants
Start Date 2021-09-15
Est. Completion 2028-12-01
Phase Phase 1

Sponsor

Celgene

308 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04884035

The ClinicalTrials.gov registry entry for NCT04884035 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 174 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 196-participant average among 31 other Lymphoma, B-Cell trials with a reported enrollment target (11% lower). The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Lymphoma, B-Cell appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.

NCT04884035 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, Florida, Kansas.

Frequently Asked Questions

What is clinical trial NCT04884035 about?

NCT04884035 is a clinical study titled "Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma". This is a Phase 1b study consisting of 2 parts: a dose escalation (Part 1) of CC-220 or CC-99282 added to the standard R-CHOP-21 regimen for first-line treatment of a-BCL. The dose escalation (Part 1) will consist of 2 parallel arms in combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincr...

What is the current status of trial NCT04884035?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 174 participants. The study started on 2021-09-15. Estimated completion is 2028-12-01.

What conditions does trial NCT04884035 study?

This clinical trial studies the following conditions: Lymphoma, B-Cell.

What interventions are being tested in trial NCT04884035?

The interventions under investigation include: Cyclophosphamide (DRUG), Doxorubicin (DRUG), Rituximab (DRUG), Vincristine (DRUG), CC-220 (DRUG).

Who is sponsoring clinical trial NCT04884035?

This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04884035 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Kansas, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lymphoma, B-Cell

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lymphoma, B-Cell

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.